Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial

The Lancet Haematology 2026

View at publisher
Authors: M Lia Palomba, Manish R Patel, Toby A. Eyre, Wojciech Jurczak, D. Lewis, Thomas Gastinne, Shuo Ma, Jonathon B Cohen, Krish Patel, Jennifer R Brown, Lydia Scarfò, Talha Munir
+27 more Ewa Lech-Maranda, Marc S Hoffmann, Chaitra S Ujjani, Bita Fakhri, Michael L Wang, Koji Izutsu, Hirokazu Nagai, Constantine S Tam, Joanna Rhodes, Julie Vose, Matthew Mckinney, James N. Gerson, Minal Barve, Bryone J. Kuss, Youngil Koh, Aisling Barrett, Steven P Treon, Jorge J. Castillo, John F Seymour, Amy S. Ruppert, Samuel McNeely, Richard A. Walgren, Donald E. Tsai, Katherine Bao, Binoj Nair, Jennifer Woyach, Chan Y Cheah
DOI: 10.1016/s2352-3026(26)00037-2
Cited by: 3
References: 29

Fields of Study & Subjects

Chronic Lymphocytic Leukemia Research Lymphoma Diagnosis and Treatment Phagocytosis and Immune Regulation

Publication details

Journal / source
The Lancet Haematology
Publisher
Elsevier BV
Volume
13
Issue
5
Pages
e284–e296
Publication date
1 May 2026
Language
EN